Find Clinical Trial

Evaluation of the effects of oral administration of ivabradine 5 mg and 7.5 mg b.i.d. in patients with heart failure and arterial hypertension insufficiently controlled by oral perindopril 4 mg per day. An open-label multicentre study.


← Back
Study Phase

Phase 2

Therapeutic Area

Cardiovascular Diseases

IndicationHeart failure
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

IVABRADINE,
S016257

Active Substance CodeS016257
Protocol CodeCL2-16257-073
EudraCT Code2006-005886-21


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2024 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility